Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy

Abstract Background Interferon (IFN) regimens for HCV treatment are less effective in HCV/HIV-coinfected patients. There are no effective treatments for patients who fail IFN therapies. We examined the safety and efficacy of peginterferon alfa-2a (peg-IFNα-2a) plus ribavirin (RBV) in 41 HCV/HIV-coin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical virology 2007-01, Vol.38 (1), p.32-38
Hauptverfasser:	Rodríguez-Torres, Maribel, Rodríguez-Orengo, José F, Ríos-Bedoya, Carlos F, Fernández-Carbia, Alberto, González-Lassalle, Elsa, Salgado-Mercado, Rosa, Marxuach-Cuétara, Acisclo M
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Allergy and Immunology Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Biological and medical sciences Drug Therapy, Combination Female Fundamental and applied biological sciences. Psychology HCV Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - virology Human immunodeficiency virus Human viral diseases Humans Infectious Disease Infectious diseases Injections, Subcutaneous Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Interferons - therapeutic use Liver biopsy Male Medical sciences Microbiology Middle Aged Miscellaneous Non-responders Peginterferon alfa-2a Polyethylene Glycols Recombinant Proteins Ribavirin Ribavirin - administration & dosage Ribavirin - adverse effects Ribavirin - therapeutic use RNA, Viral - blood Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!